DNA damage repair inhibitors for the treatment of cancer

Details DNA damage repair inhibitors for the treatment of cancer DNA damage repair inhibitors for the treatment of cancer

2004-11-30

2011-12-06

Fetterolf, Brandon (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S248000, C514S356000, C514S394000, C514S417000

Reexamination Certificate

active

08071579

ABSTRACT:
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.

REFERENCES:
patent: 5484951 (1996-01-01), Kun et al.
patent: 5519053 (1996-05-01), Kun et al.
patent: 5652367 (1997-07-01), Kun et al.
patent: 5908861 (1999-06-01), Kun
patent: 6548494 (2003-04-01), Webber et al.
patent: 7072771 (2006-07-01), Oliveira
patent: 7087637 (2006-08-01), Grandel et al.
patent: 7176188 (2007-02-01), Desnoyers
patent: 7351530 (2008-04-01), Bepler
patent: 7351701 (2008-04-01), Helleday et al.
patent: 2002/0032319 (2002-03-01), Cargill et al.
patent: 2002/0155988 (2002-10-01), O'Hare et al.
patent: 2002/0183335 (2002-12-01), Hewawasam et al.
patent: 2003/0229004 (2003-12-01), Zarling et al.
patent: 2006/0142231 (2006-06-01), Ashworth et al.
patent: 2007/0179160 (2007-08-01), Helleday
patent: 0 600 831 (1993-11-01), None
patent: 95/24379 (1995-09-01), None
patent: WO 95/24379 (1995-09-01), None
patent: 00/42040 (2000-07-01), None
patent: 01/16136 (2001-03-01), None
patent: 02/12239 (2002-02-01), None
patent: WO 92/12239 (2002-02-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 03/014090 (2003-02-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03-070234 (2003-08-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/008976 (2004-01-01), None
patent: 05/012524 (2005-02-01), None
Pinedo et al, “Translational Research . . . ”, The Oncologist 2000; 5(suppl1); 1-2. [www.The Oncologist.com].
McMahon, G., VEGF Receptor Signaling in Tumor Angiogenisis. The Oncologist 2000;5(suppl 1):3-10. [www.The Oncologist.com].
Berthet et al., “DNA repair inhibitors”, Expert Opinion on Therapeutic Patents,(1999) 9(4):401-415.
Perkins et al, “Novel inhibitros of PAR . . . ”, Cancer Res 61, 4175-4183, May 15, 2001.
Calabrese et al., “Indentificatin of Potent Nontoxic PARP Inhibitors . . . ”, Clin. Cancer Res., vol. 9, 2711-2178, Jul. 2003.
Dorwald (Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design, Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA, 2005, Preface).
Schultz et al. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Research, 2003, vol. 31, No. 17, 4959-4964.
Fan et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Research, 55, 1649-1654, Apr. 15, 1995.
Jönsson, Göran; et al., “High-Resolution Genomic Profiles of Breast Cancer Cell Lines Assessed by Tiling BAC Array Comparative Genomic Hybridization”, Genes, Chromosomes and Cancer, 2007, 46:543-558.
Sanger Institute database entry for MDA—MB-231, Catalogue of Somatic Mutations in Cancer, 2 pgs.
Turner, Nicholas; et al., “Hallmarks of ‘BRCAness’ in sporadic cancers”, Nature Reviews, Oct. 2004, 4:1-6.
Wooster, Richard; et al., “Breast and Ovarian Cancer”, The New England Journal of Medicine, Jun. 5, 2003, 348:2339-47.
Bernstein, C., et al., “DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis,” (2002)Mutation Research, 511:145-178.
Bryant, H., et al., “Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase,” (2005)Nature, 434:913-917.
Elbashir, S., et al., “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells,” (2001)Nature, 411:494-498.
Farmer, H., et al., “Targeting the DNA repair defect inBRCAmutant cells as a therapeutic strategy,” (2005)Nature, 434:917-921.
Larminat, F., et al., “Deficiency in BRCA2 leads to increase in non-conservative homologous recombination,” (2002)Oncogene, 121:5188-5192.
Massuda, E., et al., “GPI 6150, a PARP inhibitor, down-regulates metastasis associated S100A4 (Mts1) and suppresses invasion of breast cancer cells in vitro,” (2003)Proceedings of the American Association for Cancer Research, 4(2nded.):867-868.
Schultz, N., et al., “Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination,” (2003)Nucleic Acids Research, 31(17):4959-4964.
Shall, S., et al., “Ply(ADP-ribose) polymerase-1: what have we learned formt he deficient mouse model?” (2000)Mutation Research, 460:1-15.
Watchers, F., et al., “Selective targeting of homologous DNA recombination repair by gemcitabine,” (2003)Int. J. Radiation Oncology Biol. Phys., 57(2):553-562.
Weltin, D., et al, “Effect of 6(5H)-phenathridinone, as inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells,” (1994)Oncology Research, 6(9):399-403.
Gallmeier et al., Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-Ribose) Polymerase Inhibition, 2005 Cancer Biol. & Ther., 4(7): 703-706.
McCabe et al., BRCA2-Deficient CAPAN-1 Cells Are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase, 2005, Cancer Biol. & Ther., 4(9): 934-936.
Banasik, Marek; et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferase”, The Journal of Biological Chemistry, Jan. 25, 1992, 267(3):1569-1575.
Calabrese, Christopher R; et al., “Identification of Potent Nontoxic Poly (ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies”, Clinical Cancer Research, Jul. 2003, 9:2711-2718.
Cepeda, Victoria; et al., “Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy”, Recent Patents on Anti-Cancer Drug Discovery, 2006, 1:39-53.
Dillon, Krystyna J; et al., “A FlashPlate Assay for the Identification of PARP-1 Inhibitors”, J. Biomol Screen, 2003, 8(3):347-352.
Ferraris, Dana; et al., “Design and Synthesis of Poly ADP-ribose Polymerase-1 Inhibitors. 2. Biological Evaluation of Aza-5[H]-phenanthridin-6-ones as Potent, Aqueous-Soluble Compounds for the Treatment of Ischemic Injuries”, J. Med. Chem., 2003, 46:3138-3151.
Griffin, RJ; et al., “The role of inhibitors of poly (ADP-ribose) polymerase as resistance-modifying agents in cancer therapy”, Biochimie, 1995, 77:408-422.
McCabe, Nuala; et al., “Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly (ADP-Ribose) Polymerase Inhibition”, Cancer Res, Aug. 15, 2006, 66(16):8109-8115.
Turner, Nicholas; et al., “Hallmarks of ‘BRCAness’ in sporadic cancers”, Nature Reviews, Cancer, Oct. 2004, 4:1-6.
Virag, Laszlo; et al., “The Therapeutic Potential of Poly (ADP-Ribose) Polymerase Inhibitors”, Pharmacological Reviews, 2002: 54(3):375-429.
BG483078, http://mgc.nci.nih.gov/, National Institutes of Health, Mammalian Gene Collection (MGC, Unpublished, 1999, Contact: Robert Strausberg, Ph.D, Tissue Procurement: CLONTECH Laboratories, Inc.
Dudas, Andrej; et al., “DNA double-strand break repair by homologous recombination”, Mutation Research, 2004, 566:131-167.
Hoeijmakers, Jan H. J.; et al., “Genome maintenance mechanisms for preventing cancer”, Nature, May 17, 2001, 411:366-374.
Khanna, Kum Kum; et al., “DNA double-strand breaks: signaling, repair and the cancer connection”, Nature Genetics, Mar. 2001, 27:247-254.
Fong; et al., “AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study”, J Clin Oncol 26: 2008 (May 20 suppl; abstr 5510).
Hao; et al., “BRCA1-IRIS activates cyclin D1 expression in breast cancer cells by down

Affiliated with

Also associated with

Rating

DNA damage repair inhibitors for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA damage repair inhibitors for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA damage repair inhibitors for the treatment of cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4264660